Fasinumab in the treatment of hip and knee osteoarthritic pain: efficacy and safety in a 36-week randomized, double-blind placebo-controlled clinical trial. (April 2017) - Maloney, J.; Kivitz, A.; Schnitzer, T.J.; Dakin, P.; Di Martino, S.; Gao, H.; Stehman-Breen, C.; Geba, G.